Please Wait
Applying Filters...
menu
    • menu
    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-06-09

    Virtual Booth

    An Enquiry

    Menu

    Casdatifan

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Arcus Kidney Cancer Drug Casdatifan Advances to Challenge Welireg
    Arcus Kidney Cancer Drug Casdatifan Advances to Challenge Welireg

    03 Jun 2025

    // BIOSPACE

    https://www.biospace.com/drug-development/arcus-kidney-cancer-drug-casdatifan-advances-to-challenge-mercks-welireg

    BIOSPACE
    03 Jun 2025
    Share Share
    ARC-20: Casdatifan Combo Shows ~50% Response In Kidney Cancer
    ARC-20: Casdatifan Combo Shows ~50% Response In Kidney Cancer

    01 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250601016939/en/Initial-Data-from-the-ARC-20-Study-of-Casdatifan-Plus-Cabozantinib-Showed-Nearly-Half-of-Patients-with-Metastatic-Kidney-Cancer-Had-a-Confirmed-Response

    BUSINESSWIRE
    01 Jun 2025
    Share Share
    Data Demonstrated Best-in-Class Potential for Casdatifan In Kidney Cancer
    Data Demonstrated Best-in-Class Potential for Casdatifan In Kidney Cancer

    18 Feb 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250215794589/en

    BUSINESSWIRE
    18 Feb 2025
    Share Share
    Arcus Retains Casdatifan, Announces $150M Stock Offering
    Arcus Retains Casdatifan, Announces $150M Stock Offering

    18 Feb 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250218832079/en

    BUSINESSWIRE
    18 Feb 2025
    Share Share